Research and Markets has announced the addition of the "Pain Pipeline Highlights - 2017" drug pipelines to their offering.

Pain Pipeline Highlights - 2017 provides the most up-to-date information on key pipeline products in the global Pain market. It covers emerging therapies for Pain in active clinical development stages, including early- and late-stage clinical trials. The pipeline data presented in this report helps executives in tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Pain pipeline products by clinical trial stages, including both early- and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Pain pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Pain pipeline products by the company.

Short-Term Launch Highlights:

Find out which Pain pipeline products will be launched in the US and Ex-US till 2020.

Key Topics Covered:

1. Pain Pipeline by Stages

2. Pain Pipeline by Drug Class

3. Pain Pipeline by Company

4. Pain Phase 3 Clinical Trial Insights

5. Pain Phase 2 Clinical Trial Insights

6. Pain Phase 1 Clinical Trial Insights

7. Pain Preclinical Research Insights

8. Pain Discovery-Stage Insights

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/48rwb3/pain_pipeline.